CTLA‑4 blockade combined with 5‑aza‑2'‑deoxycytidine enhances the killing effect of MAGE‑A family common antigen peptide‑specific cytotoxic T cells on breast cancer

Li,Weijing; Sang,Meixiang; Hao,Xiaoguang; Wu,Yunyan; Shan,Baoen

doi:10.3892/or.2020.7701

CTLA‑4 blockade combined with 5‑aza‑2'‑deoxycytidine enhances the killing effect of MAGE‑A family common antigen peptide‑specific cytotoxic T cells on breast cancer

Authors:
- Weijing Li
- Meixiang Sang
- Xiaoguang Hao
- Yunyan Wu
- Baoen Shan
View Affiliations

Affiliations: Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Tumor Research Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: July 21, 2020 https://doi.org/10.3892/or.2020.7701
Pages: 1758-1770

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the leading cause of cancer‑associated deaths in women. Combination immunotherapy attracts great interest as a treatment for breast cancer. However, there are no studies on the use of cytotoxic T‑lymphocyte antigen 4 (CTLA‑4) monoclonal antibody in combination with the melanoma‑associated antigen A family (MAGE‑As) co‑antigen peptide (p248V9) for treating breast cancer, which should be explored. To this aim, in the present study, the samples of 115 patients with breast cancer were collected, and MAGE‑As and CTLA‑4 levels in breast cancer and adjacent normal tissues were assessed by immunohistochemical staining. The effect of 5‑aza‑2'‑deoxycytidine (5DC) on the expression of MAGE‑As in breast cancer cell lines was assessed by reverse transcription‑quantitative PCR and western blot assay. Cytotoxic T cells (CTLs) were induced by MAGE‑As co‑antigen peptide. The specific lytic rate and IFN‑γ level were examined by CCK‑8 assay and ELISA, respectively. It was found that MAGE‑As were highly expressed in breast cancer tissues. 5DC treatment promoted the expression of MAGE‑As in breast cancer cells. The upregulation of the expression of MAGE‑As specifically enhanced the ability of CTLs to kill breast cancer cells. CTLA‑4 was highly expressed in breast cancer tissues and cells, and patients with breast cancer exhibiting high expression of CTLA‑4 had low overall survival. CTLA‑4 promoted the lytic efficiency of CTLs in breast cancer cells, and the combination of an anti‑CTLA‑4 antibody and 10 µM 5DC exhibited the highest cell lysis ability of CTLs. The present study demonstrated that MAGE‑As co‑antigen peptide‑specific CTLs in combination with an anti‑CTLA‑4 monoclonal antibody and 5DC, have potent tumor cell‑killing effects. It provides a novel theory for the development of breast cancer therapies.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zeng H, Zheng R, Zhang S, Zou X and Chen W: Female breast cancer statistics of 2010 in China: Estimates based on data from 145 population-based cancer registries. J Thorac Dis. 6:466–470. 2014.PubMed/NCBI
3	Kakimi K, Karasaki T, Matsushita H and Sugie T: Advances in personalized cancer immunotherapy. Breast Cancer. 24:16–24. 2017. View Article : Google Scholar : PubMed/NCBI
4	Yang Y: Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest. 125:3335–3337. 2015. View Article : Google Scholar : PubMed/NCBI
5	Milani A, Sangiolo D, Aglietta M and Valabrega G: Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press). 6:159–168. 2014.PubMed/NCBI
6	van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
7	Schooten E, Di Maggio A, van Bergen En Henegouwen PMP and Kijanka MM: MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat Rev. 67:54–62. 2018. View Article : Google Scholar : PubMed/NCBI
8	Finn OJ: Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res. 5:347–354. 2017. View Article : Google Scholar : PubMed/NCBI
9	Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S and Jungbluth AA: Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother. 60:999–1007. View Article : Google Scholar : PubMed/NCBI
10	Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Löning T, Jänicke F and Pantel K: MAGE-A gene expression pattern in primary breast cancer. Cancer Res. 61:6682–6687. 2001.PubMed/NCBI
11	Hou SY, Sang MX, Geng CZ, Liu WH, Lü WH, Xu YY and Shan BE: Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. Arch Med Res. 45:44–51. 2014. View Article : Google Scholar : PubMed/NCBI
12	Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA and Kosmatopoulos K: Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: Implication in a broad-spectrum tumor immunotherapy. J Immunol. 169:575–580. 2002. View Article : Google Scholar : PubMed/NCBI
13	Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM and van Hall T: The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 39:44–51. 2016. View Article : Google Scholar : PubMed/NCBI
14	Villarreal DO, Chin D, Smith MA, Luistro LL and Snyder LA: Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity. Oncotarget. 8:39117–39130. 2017. View Article : Google Scholar : PubMed/NCBI
15	Davila E, Kennedy R and Celis E: Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63:3281–3288. 2003.PubMed/NCBI
16	Chen X, Shao Q, Hao S, Zhao Z, Wang Y, Guo X, He Y, Gao W and Mao H: CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 8:13703–13715. 2017. View Article : Google Scholar : PubMed/NCBI
17	Emens LA: Breast cancer immunotherapy: Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar : PubMed/NCBI
18	Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T and Lucas S: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61:5544–5551. 2001.PubMed/NCBI
19	De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, et al: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 40:360–369. 1994. View Article : Google Scholar : PubMed/NCBI
20	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
21	Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, Lian Y and Shan B: Melanoma-associated antigen genes-an update. Cancer Lett. 302:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
22	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ayyoub M, Scarlata CM, Hamai A, Pignon P and Valmori D: Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival. J Immunother. 37:73–76. 2014. View Article : Google Scholar : PubMed/NCBI
24	Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, Liu N, Tian F, Wang F and Yuan J: MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat. 145:23–32. 2014. View Article : Google Scholar : PubMed/NCBI
25	Abd-Elsalam EA and Ismaeil NA: Melanoma-associated antigen genes: A new trend to predict the prognosis of breast cancer patients. Med Oncol. 31:2852014. View Article : Google Scholar : PubMed/NCBI
26	Moreno-Bost A, Szmania S, Stone K, Garg T, Hoerring A, Szymonifka J, Shaughnessy J Jr, Barlogie B, Prentice HG and van Rhee F: Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy. 13:618–628. 2011. View Article : Google Scholar : PubMed/NCBI
27	Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P and Craddock C: Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 116:1908–1918. 2010. View Article : Google Scholar : PubMed/NCBI
28	Baecher-Allan C, Brown JA, Freeman GJ and Hafler DA: CD4+CD25 high regulatory cells in human peripheral blood. J Immunol. 167:1245–1253. 2001. View Article : Google Scholar : PubMed/NCBI
29	Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W, Deng B, Sun J, Shao Q and Qu X: New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 10:728–736. 2010. View Article : Google Scholar : PubMed/NCBI
30	Jaberipour M, Habibagahi M, Hosseini A, Habibabad SR, Talei A and Ghaderi A: Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 16:547–551. 2010. View Article : Google Scholar : PubMed/NCBI
31	Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, Vickers MA and Barker RN: The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol. 43:1274–1285. 2013. View Article : Google Scholar : PubMed/NCBI
32	Marmé FL: Immunotherapy in breast cancer. Oncol Res Treat. 39:335–345. 2016. View Article : Google Scholar : PubMed/NCBI